TORONTO, Sept. 7 /PRNewswire-FirstCall/ - The Westaim Corporation will hold a webcast at 9:00 a.m. EDT on Wednesday September 8, 2004 regarding NUCRYST Pharmaceuticals' results of its first Phase 2a human clinical trial. The investigational drug (NPI 32101) is being studied for atopic dermatitis, a form of eczema, and represents a biological application of nanotechnology. In addition to standard disclosure over wire services, a news release will be posted on the Westaim web site. To listen to the call live on the Internet, please go to www.westaim.com. Barry M. Heck, President & Chief Executive Officer, The Westaim Corporation, Scott H. Gillis, President, NUCRYST Pharmaceuticals and Dr. Paul J. Schechter, Vice President, Drug Development and Regulatory Affairs, Chief Medical Officer, NUCRYST Pharmaceuticals will participate on the call. An audio file of the call will be archived and posted on the Westaim web site. NUCRYST Pharmaceuticals Corp. (www.nucryst.com) researches and develops pharmaceutical products based on noble metal nanocrystalline technology. Potential products are in development for dermatology and severe respiratory conditions. The company has also profitably commercialized its technology for wound care with Acticoat(TM) antimicrobial dressings for serious wounds including life-threatening burns, using NUCRYST's proprietary SILCRYST(TM) nanocrystalline technology. These products are marketed, sold and distributed by Smith & Nephew, the world's leading advanced wound care company. In addition to NUCRYST Pharmaceuticals, The Westaim Corporation's technology investments include iFire Technology, which has developed a revolutionary low-cost flat panel display. Westaim's common shares are listed on NASDAQ under the symbol WEDX and on The Toronto Stock Exchange under the trading symbol WED.
SOURCE Westaim Corporation